



Last Update: Spring 2006

The following tables, which will be updated periodically, represent observations of deleterious mutations by Myriad Genetic Laboratories through its clinical testing service. Data obtained through testing performed under specific research protocols is not included here. The information included in these tables was obtained from a routine laboratory requisition form and has not been independently verified by Myriad Genetic Laboratories. Patients for whom relevant information was not provided were not included in this tabulation. Table 2 includes patients tested only for three prevalent founder mutations as well as patients tested by full sequence analysis. The method used to develop the prevalence tables has been published in, Frank TS et al: Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals. Journal of Clinical Oncology. 20: 1480-1490, 2002. Please contact clinresearch@myriad.com or call 1-800-469-7423 with any questions or comments.

1. The Prevalence of Deleterious Mutations in BRCA1 and BRCA2 (Excludes Individuals of Ashkenazi Ancestry)

Patient's History	Family History (Includes at least one first or second degree relative)					
	No breast cancer <50, or ovarian cancer, in any relative. [†]	Breast cancer <50 in one relative; no ovarian cancer in any relative.	Breast cancer <50 in more than one relative; no ovarian cancer in any relative.	Ovarian cancer at any age in one relative; no breast cancer <50 in any relative.	Ovarian cancer in more than one relative; no breast cancer <50 in any relative.	Breast cancer <50 and ovarian cancer at any age. ^{††}
No breast cancer or ovarian cancer at any age	72/2547	154/3396	295/3383	87/1547	93/973	420/3431
Breast cancer ≥ 50	61/2082	121/2292	142/1248	61/956	29/238	166/1042
Breast cancer <50	597/8809	789/4990	842/2795	319/1888	108/396	904/2309
Male breast cancer	37/289	22/101	18/43	6/30	2/5	13/21
Ovarian cancer at any age, no breast cancer	99/1129	111/481	99/234	127/601	75/226	230/495
Breast cancer ≥50 and ovarian cancer at any age	53/301	30/115	24/52	23/76	12/26	42/70
Breast cancer <50 and ovarian cancer at any age	75/192	55/102	41/61	35/53	17/24	79/100

[†] May include families with breast cancer ≥50 (in women or men).

Number of observations in Table 1 is 49149

^{††} Includes family members with either or both diagnoses.

2. The Prevalence of Deleterious Mutations in BRCA1 and BRCA2 in Individuals of Ashkenazi Ancestry

Patient's History	Family History (Includes at least one first or second degree relative)					
	No breast cancer <50, or ovarian cancer, in any relative. [†]	Breast cancer <50 in one relative; no ovarian cancer in any relative.	Breast cancer <50 in more than one relative; no ovarian cancer in any relative.	Ovarian cancer at any age in one relative; no breast cancer <50 in any relative.	Ovarian cancer in more than one relative; no breast cancer <50 in any relative.	Breast cancer <50 and ovarian cancer at any age. ^{††}
No breast cancer or ovarian cancer at any age	125/1814	261/1908	219/1101	179/1149	94/398	367/1336
Breast cancer ≥ 50	64/1443	58/618	25/221	35/221	8/40	37/186
Breast cancer <50	245/2037	172/711	136/355	119/307	29/49	146/284
Male breast cancer	16/107	8/26	0/4	6/15	3/3	7/10
Ovarian cancer at any age, no breast cancer	95/428	34/92	20/33	50/119	16/37	60/83
Breast cancer ≥50 and ovarian cancer at any age	23/78	9/14	4/8	6/12	2/2	7/11
Breast cancer <50 and ovarian cancer at any age	27/38	16/18	4/5	10/11	1/1	9/12

[†] May include families with breast cancer ≥50 (in women or men).

Number of observations in Table 2 is 15345

^{††} Includes family members with either or both diagnoses.

Table 2 includes individuals that tested for MultiSite3, which may have been for a known mutation in the family